HNSCC | Nano Publications

2018 – OncoRad – NBXTR3 in HNSCC and NSCLC with anti-PD1

Clinical Data NBTXR3, Congress Abstracts, Head & Neck, Lung

Recent clinical studies have demonstrated the efficacy of anti-PD-1 in recurrent/metastatic HNSCC and upfront metastatic NSCLC patients. However, most patients with recurrent/metastatic HNSCC demon-strate innate (primary) resistance to checkpoint inhibition and do not respond to initial therapy and only a subset of metastatic HNSCC/NSCLC patients benefits from this treatment. […]

2018 – SIOG – NBTXR3 In Elderly With HNSCC

Clinical Data NBTXR3, Congress Abstracts, Head & Neck

Compared to younger individuals, elderly patients with head and neck squamous cell carcinoma (HNSCC) have limited therapeutic options. Despite representing approximately 47% of the affected population with an increasing incidence, older patients are underrepresented from HNSCC prospective clinical trials further limiting their therapeutic options. […]

2018 – ASTRO 2018 – NBTXR3 in elderly HNSCC

Clinical Data NBTXR3, Congress Abstracts, Head & Neck

As the incidence of head and neck squamous cell carcinoma (HNSCC) increases with age, elderly patients represent 25% of the affected population with an expected increase in the next 20 years. Being more vulnerable to treatment-induced toxicities, the elderly cannot be treated like younger patients, hence requiring innovative therapies. […]

2018 – ESMO 2018 – NBTXR3 in elderly HNSCC

Clinical Data NBTXR3, Congress Abstracts, Liver

Elderly patients (pts) with head and neck squamous cell carcinoma (HNSCC) represent 25% of the affected population. They are not always eligible to the same treatment of younger pts, thus require new therapies. NBTXR3, injectable hafnium oxide nanoparticles activated by radiotherapy (RT), was developed to increase the local deposit of energy within the tumor. […]

2018 – ECHNO 2018 – NBTXR3 for elderly and frail HNSCC patients

Clinical Data NBTXR3, Congress Abstracts, Head & Neck

NBTXR3 administered as a single intratumoral injection and activated by radiotherapy, is currently evaluated in a phase I clinical trial for head and neck cancer. At the 2018 Multidisciplinary Head and Neck Cancers Symposium in Scottsdale Arizona, preliminary results were presented by prof. C. Le Tourneau. […]

2018 – ESTRO – Hafnium Oxide Nanoparticles and Radiotherapy: A Promising New Treatment Strategy

Clinical Data NBTXR3, Congress Abstracts, Head & Neck, Liver, Rectum, STS

With recent advances in radiation delivery techniques, an increasing number of cancer patients undergo radiotherapy. However, due to the non-targeted nature of radiotherapy, doses are limited by potential toxicity to surrounding normal tissue. Thus, a major challenge remains to develop new strategies to improve the tumor selectivity of radiation therapy. […]

2018 – Multidisciplinary H&N – NBTXR3 for Head and Neck Cancer

Clinical Data NBTXR3, Congress Abstracts, Head & Neck

2017 – Abstract – THNO – NBTXR3 in combination with IMRT in patients with locally advanced HNSCC

Clinical Data NBTXR3, Congress Abstracts, Head & Neck

At the 2017 THNO in Nice, France, prof. C. Le Tourneau presented preliminary results of NBTXR3 in patients suffering from HNSCC. The treatment was associated with a positive safety profile, and preliminary effiacy evaluation, the local Complete Response rate is 83 % (dose level15% and 22%), with a duration of response of 22 months. […]